One of the deadliest and scariest diseases in the world may soon be a thing of the past, thanks to a team of U.S and Canadian researchers. When uplifting news is in short supply, a victory over Ebola is excellent news indeed.
The new Ebola vaccine is proven 100 percent effective in trials. The Lancet medical journal and drug maker Merck & Co. now has a stockpile of 300,000 doses in case of future outbreaks.
That should come as a relief for all of us around the world, regardless of our exposure levels. We expect the vaccine to be approved by the World Health Organization and U.S Food and Drug Administration by 2018.
The extremely contagious virus was first discovering in the former Zaire(The Democratic Republic of the Congo) in 1976. Ebola is responsible for over 11,300 deaths in 2015 from an outbreak in Sierra Leone, Liberia, and Guinea.
The symptoms begin with a fever, headache, and sore throat. Then it’s following by rashes, vomiting, internal and external bleeding, and organ failure. The disease has a 50-90 percent mortality rate, and once symptoms appear, victims only have 6-16 days to either defeat the virus or die.
Now, a life-changing vaccine promises to stop the deadliest subtype of the virus. The vaccine carries Ebola DNA that triggers an immune response.
Out of 5,873 exposed individuals given the vaccine in 2015, none have contracted the virus to date.
The vaccine trials, which could have taken almost a decade, were complete in less than two years thanks to an international effort of researchers. The U.S. Army and Canada’s public health agency developed the vaccine, with the patent issued to Merck.
The effectiveness of the vaccine is a miraculous outcome according to Dr. Jeremy Farrar of the Wellcome Trust, one of many organizations involved in the trials.